Zanamivir Hydrate
Zanamivir hydrate is a hydrated form of zanamivir, an inhaled neuraminidase inhibitor that blocks influenza virus neuraminidase to prevent viral release and spread within the respiratory tract. The hydrate form represents a physicochemical state of the molecule used in pharmaceutical characterization and manufacturing. Clinically, it is equivalent in activity to anhydrous zanamivir for treatment and prevention of influenza infections.
Peso molecular
350,3300 g/mol
TPSA
202,00 Ų
Mecanismo de acción
Inhibits viral neuraminidase, preventing the release of newly formed virus particles from infected cells and limiting viral spread within the respiratory tract.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral neuraminidase, preventing the release of newly formed virus particles from infected cells and limiting viral spread within the respiratory tract.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N.O
InChI
InChI=1S/C12H20N4O7.H2O/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17;/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16);1H2/t5-,6+,8+,9+,10+;/m0./s1
Molecular Formula
C12H22N4O8
HBD / HBA
8 / 9
Enlaces Rotables
6
Átomos Pesados
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Zanamivir hydrate is a hydrated form of zanamivir, an inhaled neuraminidase inhibitor that blocks influenza virus neuraminidase to prevent viral release and spread within the respiratory tract. The hydrate form represents a physicochemical state of the molecule used in pharmaceutical characterization and manufacturing. Clinically, it is equivalent in activity to anhydrous zanamivir for treatment and prevention of influenza infections.
Inhibits viral neuraminidase, preventing the release of newly formed virus particles from infected cells and limiting viral spread within the respiratory tract.
Yes, Zanamivir Hydrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315117. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 636424. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="zanamivir-hydrate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/zanamivir-hydrate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/zanamivir-hydrate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/zanamivir-hydrate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="zanamivir-hydrate"></drugfyi-drug>